PROQR THERAPEUTICS NV (PRQR) Stock Price, Quote, News and Overview
NASDAQ:PRQR - Nasdaq - NL0010872495 - Common Stock - Currency: USD
PRQR Quote, Performance and Key Statistics
NASDAQ:PRQR (6/20/2025, 8:00:00 PM)
1.93
-0.01 (-0.52%)
The current stock price of PRQR is 1.93 USD. In the past month the price increased by 12.21%. In the past year, price increased by 12.87%.
PRQR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About PRQR
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Company Info
PROQR THERAPEUTICS NV
Zernikedreef 9
Leiden ZUID-HOLLAND 2333 CK NL
CEO: Daniel de Boer
Employees: 166
Phone: 31881667000
PROQR THERAPEUTICS NV / PRQR FAQ
What is the stock price of PROQR THERAPEUTICS NV today?
The current stock price of PRQR is 1.93 USD. The price decreased by -0.52% in the last trading session.
What is the ticker symbol for PROQR THERAPEUTICS NV stock?
The exchange symbol of PROQR THERAPEUTICS NV is PRQR and it is listed on the Nasdaq exchange.
On which exchange is PRQR stock listed?
PRQR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROQR THERAPEUTICS NV stock?
15 analysts have analysed PRQR and the average price target is 9.18 USD. This implies a price increase of 375.65% is expected in the next year compared to the current price of 1.93. Check the PROQR THERAPEUTICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROQR THERAPEUTICS NV worth?
PROQR THERAPEUTICS NV (PRQR) has a market capitalization of 203.06M USD. This makes PRQR a Micro Cap stock.
How many employees does PROQR THERAPEUTICS NV have?
PROQR THERAPEUTICS NV (PRQR) currently has 166 employees.
What are the support and resistance levels for PROQR THERAPEUTICS NV (PRQR) stock?
PROQR THERAPEUTICS NV (PRQR) has a support level at 1.89 and a resistance level at 2. Check the full technical report for a detailed analysis of PRQR support and resistance levels.
Is PROQR THERAPEUTICS NV (PRQR) expected to grow?
The Revenue of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -12.58% in the next year. Check the estimates tab for more information on the PRQR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROQR THERAPEUTICS NV (PRQR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRQR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRQR, evaluating the profitability, health, valuation and growth aspects
- PROQR THERAPEUTICS NV (PRQR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROQR THERAPEUTICS NV (PRQR) Sales and EPS estimates to see what analysts future expectations are.
- PROQR THERAPEUTICS NV (PRQR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROQR THERAPEUTICS NV (PRQR) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROQR THERAPEUTICS NV (PRQR) Stock Chart to make your own analysis
- PROQR THERAPEUTICS NV (PRQR) Latest news and press-releases to stay up to date.
Does PROQR THERAPEUTICS NV (PRQR) stock pay dividends?
PRQR does not pay a dividend.
When does PROQR THERAPEUTICS NV (PRQR) report earnings?
PROQR THERAPEUTICS NV (PRQR) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of PROQR THERAPEUTICS NV (PRQR)?
PROQR THERAPEUTICS NV (PRQR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the Short Interest ratio of PROQR THERAPEUTICS NV (PRQR) stock?
The outstanding short interest for PROQR THERAPEUTICS NV (PRQR) is 0.68% of its float. Check the ownership tab for more information on the PRQR short interest.
PRQR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRQR. When comparing the yearly performance of all stocks, PRQR is one of the better performing stocks in the market, outperforming 81.9% of all stocks.
PRQR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRQR. PRQR may be in some trouble as it scores bad on both profitability and health.
PRQR Financial Highlights
Over the last trailing twelve months PRQR reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 1.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.9% | ||
| ROE | -38.24% | ||
| Debt/Equity | 0.14 |
PRQR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to PRQR. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -25.25% and a revenue growth -12.58% for PRQR